EnteroMedics Inc (NASDAQ:ETRM) , which happens to be one of the leading developers of medical devices using neuroblocking technology targeting facing out the various metabolic diseases, obesity as well as the gastrointestinal disorders has today made a very important announcement.
It has come out clearly to state that the McGuire Veterans Affairs Medical Center (Richmond VAMC) located in Richmond, VA has moved ahead to actually complete its first critical implant of the Company’s vBloc® Neurometabolic Therapy and of course this is a positive step forward. According to sources, the surgery was carried out this week.
The Managing Director, James Maher while speaking to a number of news reporters said, “Providing the best medical options to combat morbid obesity to the men and women who have served our country is a top priority and with vBloc Therapy available at the Richmond VAMC, we are now able to provide a safe and effective alternative to invasive, anatomy-altering and restricting procedures. There are well over one million veterans with obesity and the Richmond VAMC is committed to helping those in our communities succeed in their fight against obesity.”
The vBloc System is such that it in a great fashion performs its functions which helps exercise control over sensations of hunger and this is made possible by the use of a pacemaker-like device usually implanted under the skin.
It is worth noting that it actually needs to be a safe, minimally-invasive procedure in opposition to those procedures that end up altering or otherwise removing the anatomy of the patient in question.
It is also possible to adjust the device so that it is able to optimize patients’ therapy needs and at the same time make the patient experience a sensation of fullness and in that particular regard they are able to control their appetite and thus they can succeed in their quest to lose weight.
A series of studies have come about with major revelations. For instance, the vBloc Therapy has been indicated to actually produce some meaningful weight loss in patients not forgetting that the meaningful improvements that are associated with comorbidity factors.
Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact firstname.lastname@example.org.